Entrada Therapeutics Inc [NASDAQ: TRDA] stock went on a downward path that fall over -0.40% on Wednesday, amounting to a one-week price increase of more than 15.46%.
Over the last 12 months, TRDA stock dropped by -41.70%. The one-year Entrada Therapeutics Inc stock forecast points to a potential upside of 38.91. The average equity rating for TRDA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $385.25 million, with 38.22 million shares outstanding and 22.99 million shares in the current float. Compared to the average trading volume of 284.24K shares, TRDA stock reached a trading volume of 153968 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Entrada Therapeutics Inc [TRDA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRDA shares is $16.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRDA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH MKM have made an estimate for Entrada Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 06, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on January 05, 2024, representing the official price target for Entrada Therapeutics Inc stock. Previously, the target price had yet another raise to $25, while H.C. Wainwright analysts kept a Buy rating on TRDA stock.
The Price to Book ratio for the last quarter was 1.13, with the Price to Cash per share for the same quarter was set at 8.55.
TRDA Stock Performance Analysis:
Entrada Therapeutics Inc [TRDA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.46. With this latest performance, TRDA shares gained by 37.14% in over the last four-week period, additionally plugging by 27.59% over the last 6 months – not to mention a drop of -41.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TRDA stock in for the last two-week period is set at 77.14, with the RSI for the last a single of trading hit 0.67, and the three-weeks RSI is set at 0.58 for Entrada Therapeutics Inc [TRDA]. The present Moving Average for the last 50 days of trading for this stock 6.92, while it was recorded at 9.87 for the last single week of trading, and 7.71 for the last 200 days.
Insight into Entrada Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Entrada Therapeutics Inc [TRDA] shares currently have an operating margin of -194.50% and a Gross Margin at 93.11%. Entrada Therapeutics Inc’s Net Margin is presently recorded at -168.16%.
Entrada Therapeutics Inc (TRDA) Capital Structure & Debt Analysis
According to recent financial data for Entrada Therapeutics Inc. ( TRDA), the Return on Equity (ROE) stands at -27.11%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -21.39%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Entrada Therapeutics Inc’s Return on Invested Capital (ROIC) is -26.61%, showcasing its effectiveness in deploying capital for earnings.
Entrada Therapeutics Inc (TRDA) Efficiency & Liquidity Metrics
Based on Entrada Therapeutics Inc’s (TRDA) latest financial statements, the Debt-to-Equity Ratio is 0.15%, indicating its reliance on debt financing relative to shareholder equity.
Entrada Therapeutics Inc (TRDA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Entrada Therapeutics Inc. (TRDA) effectively leverages its workforce, generating an average of -$565300.55 per employee. The company’s liquidity position is robust, with a Current Ratio of 14.08% and a Quick Ratio of 14.08%, indicating strong ability to cover short-term liabilities.
TRDA Stock EPS
With the latest financial reports released by the company, Entrada Therapeutics Inc posted 0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.69. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TRDA.
Entrada Therapeutics Inc [TRDA] Institutonal Ownership Details
There are presently around $74.94%, or 85.40%% of TRDA stock, in the hands of institutional investors. The top three institutional holders of TRDA stocks are: BAKER BROS. ADVISORS LP with ownership of 4.87 million shares, which is approximately 14.2356%. MPM ASSET MANAGEMENT LLC, holding 4.43 million shares of the stock with an approximate value of $$63.07 million in TRDA stocks shares; and MPM ASSET MANAGEMENT LLC, currently with $$62.82 million in TRDA stock with ownership which is approximately 12.8973%.
